PharmaSGP is a pure-play consumer health company with a broad portfolio of leading natural non-prescription pharmaceuticals sold over the counter (“OTC”) and other healthcare products. PharmaSGP’s products are mainly sold through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.
The Company’s core brands in the category „Health Brands“ cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic natural pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. The DESEO® and Neradin® brands are aimed at the men’s health market. Since September 2021, the brands Baldriparan®, Formigran®, Spalt® and Kamol® are part of the PharmaSGP portfolio. With the No. 1* herbal sleep aid in Germany Baldriparan®, PharmaSGP expands its portfolio and enters the sleep disorder category. Formigran®, Spalt® and Kamol® expand the product range in the important category "pain therapy".
PharmaSGP has established an asset-light business model that ensures decidedly substantial scalability with a highly efficient cost structure. Years of in-depth regulatory experience make it possible to quickly integrate OTC products of the most diverse categories into the portfolio and launch onto markets. As a D2C specialist, PharmaSGP achieves a very wide coverage among relevant target groups with over 100 million contacts per month – and all this under attractive and efficient media conditions.
Drawing on these strengths, PharmaSGP has been generating continuous and profitable growth of the „Health Brands“ for many years. In 2020 PharmaSGP generated revenues of 63.2 € million at an EBIT margin of 26%.
PharmaSGP's growth strategy aims to make efficient use of the pan-European platform.
On the one hand, PharmaSGP is constantly expanding the number of indications covered by its product range, while on the other, PharmaSGP is pushing expansion within Europe. Apart from the further organic growth of the existing „Health Brands“, PharmaSGP will focus on the acquisition and integration of established brands in future.
The acquisition of the OTC brand portfolio (Baldriparan®, Formigran®, Spalt® and Kamol®) from the GlaxoSmithKline Group in September 2021 is part of the successful M&A strategy. Strategically, PharmaSGP is strengthening its business by further expanding the "Health Brands" category, extending the therapeutic areas and opening up new markets in Europe. In the future, the SGP Group will also be active in Switzerland, Hungary, Poland, the Czech Republic and Slovakia.